AU Stock MarketDetailed Quotes

IMM Immutep Ltd

Watchlist
  • 0.320
  • -0.005-1.54%
20min DelayMarket Closed Dec 2 16:00 AET
465.46MMarket Cap-8888P/E (Static)

About Immutep Ltd Company

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Company Profile

SymbolIMM
Company NameImmutep Ltd
Founded1987
MarketASX
Employees44
Fiscal Year Ends06-30
Address264 George Street Level 32, Australia Square
CitySydney
CountryAustralia
Zip Code2000
Phone+61 283157003
Websitehttps://www.immutep.com
Share RegistryBOARDROOM PTY LIMITED LEVEL 8, 210 GEORGE STREET, SYDNEY, NSW, AUSTRALIA, 2000 (02) 9290 9600

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer and Chief Financial Officer
  • 1.06M
  • Dr. Florian Vogl, M.D.,PhD
  • Chief Medical Officer
  • 955.82K
  • Professor Dr. Frederic Triebel, M.D.
  • Executive Director and Chief Scientific Officer
  • 864.44K
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 565.23K
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 138.71K
  • Dr. Russell J. Howard, PhD
  • Chairman of the Board
  • 222.02K
  • Lis Boyce
  • Independent Director
  • 144.76K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
AU
Overall
Symbol
Latest Price
% Chg

No Data